12.1 Severity of scars (12 months) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
12.1.1 Mean percentage reduction in Observer Assessment score (12 months) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
12.1.2 Mean percentage reduction in Patient Self‐Assessment score (12 months) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
12.1.3 Mean percentage reduction in Vancouver Burn Scale (VBS) score (12 months) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
12.2 Incidence and severity of treatment‐related adverse effects (12 months) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
12.2.1 Atrophy (12 months) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
12.2.2 Erythema (12 months) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
12.2.3 Telangiectasia (12 months) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
12.2.4 Hypopigmentation (12 months) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
12.3 Scar size, colour, height, length, width and pliability, skin surface texture, pruritus and pain(12 months) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
12.3.1 Mean percentage reduction of scar height (12 months) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
12.3.2 Mean percentage reduction of scar volume (12 months) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
12.4 Recurrence of the condition (12 months) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |